172 related articles for article (PubMed ID: 28705617)
21. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
22. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
23. Preparation of a novel lipid-core micelle using a low-energy emulsification method.
Fritz HF; Ortiz AC; Velaga SP; Morales JO
Drug Deliv Transl Res; 2018 Dec; 8(6):1807-1814. PubMed ID: 29663150
[TBL] [Abstract][Full Text] [Related]
24. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
25. Improvement of drug safety by the use of lipid-based nanocarriers.
Lim SB; Banerjee A; Önyüksel H
J Control Release; 2012 Oct; 163(1):34-45. PubMed ID: 22698939
[TBL] [Abstract][Full Text] [Related]
26. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. II. Evaluation of the imidazole antifungal drug-loaded nanoparticle dispersions and their gel formulations.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105102. PubMed ID: 24531828
[TBL] [Abstract][Full Text] [Related]
27. Nanocarrier for poorly water-soluble anticancer drugs--barriers of translation and solutions.
Narvekar M; Xue HY; Eoh JY; Wong HL
AAPS PharmSciTech; 2014 Aug; 15(4):822-33. PubMed ID: 24687241
[TBL] [Abstract][Full Text] [Related]
28. Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.
Rao S; Richter K; Nguyen TH; Boyd BJ; Porter CJ; Tan A; Prestidge CA
Mol Pharm; 2015 Dec; 12(12):4424-33. PubMed ID: 26523928
[TBL] [Abstract][Full Text] [Related]
29. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
30. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
[TBL] [Abstract][Full Text] [Related]
31. Lipid nanoparticles for administration of poorly water soluble neuroactive drugs.
Esposito E; Drechsler M; Mariani P; Carducci F; Servadio M; Melancia F; Ratano P; Campolongo P; Trezza V; Cortesi R; Nastruzzi C
Biomed Microdevices; 2017 Sep; 19(3):44. PubMed ID: 28526975
[TBL] [Abstract][Full Text] [Related]
32. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
33. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.
Sahbaz Y; Williams HD; Nguyen TH; Saunders J; Ford L; Charman SA; Scammells PJ; Porter CJ
Mol Pharm; 2015 Jun; 12(6):1980-91. PubMed ID: 25905624
[TBL] [Abstract][Full Text] [Related]
34. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
35. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of Solid Dispersion in Solid Lipid Particles for Dissolution Enhancement of Poorly Water-Soluble Drug.
My Tran KT; Vo TV; Lee BJ; Duan W; Ha-Lien Tran P; Truong-Dinh Tran T
Curr Drug Deliv; 2018; 15(4):576-584. PubMed ID: 28595530
[TBL] [Abstract][Full Text] [Related]
37. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
38. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro.
Meola TR; Dening TJ; Prestidge CA
Eur J Pharm Biopharm; 2018 Aug; 129():145-153. PubMed ID: 29857135
[TBL] [Abstract][Full Text] [Related]
39. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.
Mishra A; Imam SS; Aqil M; Ahad A; Sultana Y; Ameeduzzafar ; Ali A
Drug Deliv; 2016 May; 23(4):1486-94. PubMed ID: 26978072
[TBL] [Abstract][Full Text] [Related]
40. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
Gonçalves LM; Maestrelli F; Di Cesare Mannelli L; Ghelardini C; Almeida AJ; Mura P
Eur J Pharm Biopharm; 2016 May; 102():41-50. PubMed ID: 26925503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
